Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eOD-GT8 60mer Vaccine in Healthy Adults
NCT03547245Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eOD-GT8 60mer mRNA vaccine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Frequency of local and systemic reactogenicity events at 7 days, Proportion of volunteers with moderate or greater unsolicited adverse events at 16 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
eOD-GT8 60mer mRNA vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03547245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547245.